Physician profile
Brooks Wiley
NPI 1003267923
$2,927.01
in general payments reported to CMS, 2019-2025
28 companies · $837 in 2025
The $837 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $419 · 2022: $277 · 2023: $683 · 2024: $711 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,231.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $571.71 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $270.47 | 2021-2025 | Ingrezza |
| Corium, LLC | $223.88 | 2023-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $190.29 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ironshore Pharmaceuticals INC. | $173.33 | 2023-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $167.77 | 2023-2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $158.50 | 2022-2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $151.55 | 2023-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $116.53 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $90.88 | 2021 | |
| Alkermes, INC. | $84.54 | 2021-2025 | Aristada, Lybalvi |
| Braeburn INC. | $82.98 | 2024-2025 | Brixadi |
| Otsuka America Pharmaceutical, INC. | $78.07 | 2021-2025 | Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $70.58 | 2025 | Fanapt |
| Indivior INC. | $63.05 | 2021-2025 | Sublocade |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $60.55 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.50 | 2023 | Caplyta |
| Tempus Ai, INC | $51.43 | 2024-2025 | Xt Cdx |
| Biogen, INC. | $43.41 | 2025 | Zurzuvae |
| E.R. Squibb & Sons, L.L.C. | $39.27 | 2025 | Cobenfy |
| Adlon Therapeutics L.P. | $31.49 | 2021 | |
| Alfasigma USA, INC. | $29.67 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $27.09 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.05 | 2023 | Aplenzin |
| Sunovion Pharmaceuticals INC. | $20.47 | 2022 | |
| Tris Pharma INC | $19.95 | 2025 | Dyanavel Xr |
| Almatica Pharma LLC | $18.02 | 2022 | |
| Merck Sharp & Dohme LLC | $13.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooks Wiley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.